Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was down 19.4% on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares were traded during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Trading Down 7.9 %
The company has a market cap of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a 50-day moving average of C$0.20 and a 200 day moving average of C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Short Selling: How to Short a Stock
- Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 02/17 – 02/21
- How to trade using analyst ratings
- SolarEdge: A Surprising Bright Spot in a Troubled Solar Industry?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
